Articular cartilage has a very poor self-regenerating capacity because it is devoid of any vasculature; once cartilage is damaged, injuries tend to progress due to the lack of self-regeneration. The only damage repaired by conventional cartilage products is the thin cartilage layer on the surface of the joint. Therefore, if the damage extends to the subchondral bone layer supporting the cartilage layer, the only available option is symptomatic therapy, which involves replacement with an artificial joint or follow-up.
The cell-based osteochondral structure currently under clinical development by Cyfuse is grafted to a defect. It has been shown that after grafting, the cells themselves gradually differentiate into cartilage and bone, and simultaneously regenerate the various tissues of the subchondral bone supporting the cartilage and cartilage layer, thus showing considerable promise for improving the QOL (quality of life) of patients for whom effective treatment has been thus far unavailable.

Cyfuse is working on the development of new treatment options for minimizing the risk and toll of infections, for which “small-diameter cell-based blood vessels” are transplanted as alternatives to artificial blood vessels in patients who require blood transfusions due to renal failure, for example.
The results of research on cell-based vascular structures currently under joint clinical development by Cyfuse and Saga University Hospital, with the support of AMED, have been published in Nature Communications, etc., and indicate that these types of infection-resistant and highly elastic cell-based blood vessels show considerable promise as new treatment options for dialysis patients with vascular disorders, including diabetes.

Cyfuse is working on the development of a new treatment option for regenerating torn nerves for sensory nerve and motor nerve enhancement, wherein “cell-based nerve conduits” are grafted in patients needing limb function recovery from peripheral nerve damage, for example.
The results of research on cell-based neural structures (nerve conduits) currently under joint clinical development by Cyfuse and Kyoto University Hospital, with the support of AMED, have been published in Scientific Report, Cell Transplants, Microsurgery, etc., as well as in the electronic US academic journal PLOS ONE and the US science journal Newton; they indicate that these structures show considerable promise as new treatment options for promoting the regeneration of native nerves without sacrificing native healthy tissue in people with torn nerves from accidents or tumor resection and those for whom autologous nerve grafts are not feasible.